Biogen second-quarter profit rises 11 percent
NEW YORK (Reuters) - Biogen Idec Inc , which this month fended off activist investor Carl Icahn's attempt to place three hand-picked candidates on the board, on Tuesday said second-quarter profit rose 11 percent on strong sales of its multiple sclerosis and cancer drugs.
<p><img src="http://feeds.reuters.com/~a/reuters/businessNews?i=pXHDXe" border="0"></img> (http://feeds.reuters.com/~a/reuters/businessNews?a=pXHDXe)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/businessNews?i=lXs8WJ" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=lXs8WJ) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=FtoGij" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=FtoGij) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=jYIRij" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=jYIRij)
</div><img src="http://feeds.reuters.com/~r/reuters/businessNews/~4/342470749" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/businessNews/~3/342470749/idUSWNAB161520080722